A Phase 2b dose-evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Closed to Enrollment
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Pazopanib eye drops to adults with Wet AMD compared to Ranibizumab injections.
Ages Eligible for Study: 50 years old and older
Genders Eligible for Study: Both
Subject has the diagnosis of ACTIVE Wet (Exudative) AMD.
Must have had at least three prior injections of Lucentis, Macugen or Avastin for treatment for the Wet AMD.
Aged 50 to 75 years.
Relatively good general medical health.